We are pleased to announce the release of Vitrolife Group’s Annual Report for 2025. Despite a volatile market, we delivered a resilient performance, continued to gain market share in key regions, and maintained our strategic focus on growth, innovation, and operational excellence.
Annual Report
Vitrolife Group Annual and Sustainability Report for 2025
Latest financial report
Interim report Q1, 2026: Strong growth in Consumables and Technologies
A good start to the year with 5% organic growth in local currencies, building on solid momentum and proactively navigating dynamic market conditions, while maintaining a clear focus on executing our long-term strategy.
Excellence in reproductive health
By combining Igenomix’s reproductive genetic testing services with Vitrolife’s IVF medical devices, we are now better than ever positioned to serve our customers and their patients, so that more families can fulfil the dream of having a healthy baby.
Reasons to invest in Vitrolife Group
- Underlying resilient market growth.
- High quality brands linked with outstanding service and support.
- Proven track record of profitable growth.
- Innovation and technology leader within fertility.
- Ambitious strategy and long-term objectives.
Press Releases
Financial Calendar
-
16 Jul 2026
Interim report Q2, 2026
-
22 Oct 2026
Interim report Q3, 2026
-
28 Jan 2027
Fourth quarter and full year report 2026
IR Contact
Jenny Jakobson
Welcome to contact us if you have questions about the Vitrolife Group in relation to investments and the listing on Nasdaq Stockholm.
Financial Reports
Read Vitrolife Group's financial reports, including the latest release of the annual and sustainability report and interim reports.
Sustainability
Ensuring sustainability in everything we do is one of our key strategic priorities. Learn more on our approach and sustainability themes.
Corporate governance
Vitrolife AB is a publicly traded Swedish company listed on NASDAQ Stockholm. The company's corporate governance policies comply with Swedish laws and regulations.